Developing an alemtuzumab infusion unit for patients with multiple sclerosis
| Autor: | Maria Espasandin |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
business.industry Multiple sclerosis Multiple dosing medicine.disease Infusion Unit 03 medical and health sciences 0302 clinical medicine medicine Alemtuzumab 030212 general & internal medicine Neurology (clinical) Intensive care medicine business 030217 neurology & neurosurgery General Nursing medicine.drug |
| Zdroj: | British Journal of Neuroscience Nursing. 15:180-183 |
| ISSN: | 2052-2800 1747-0307 |
| DOI: | 10.12968/bjnn.2019.15.4.180 |
| Popis: | Treating multiple sclerosis (MS) with alemtuzumab involves multiple dosing cycles and long-term safety monitoring. With the NHS being under increasing financial pressure, there is the potential for gaps to form between national guidelines for MS treatment and service provision, making it difficult for patients with MS who are eligible to receive treatments like alemtuzumab. In this article, we share our experiences of setting up an alemtuzumab infusion unit at The Royal London Hospital. We created a collaborative partnership with industry, based on the mutual goal of optimising access to alemtuzumab for all eligible patients who would like to receive it. This agreement involved the provision of additional nursing support and a roaming phlebotomy service by Sanofi Genzyme (formerly Genzyme), and careful planning of the hospital's support requirements on a month-by-month basis. The success of the partnership has been reflected by the complete clearance of the patient waiting list for alemtuzumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|